Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of thoracic disease"
DOI: 10.21037/jtd.2018.04.162
Abstract: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related morbidity and mortality worldwide (1). Epidermal growth factor receptor ( EGFR ) mutations, as driver oncogenes, were first identified in NSCLC in 2004 (2). read more here.
Keywords: lung adenocarcinoma; adenocarcinoma patient; patient egfr; kinase domain ... See more keywords
NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
Sign Up to like & getrecommendations! Published in 2019 at "OncoTargets and therapy"
DOI: 10.2147/ott.s192367
Abstract: The heterogeneity of ALK tyrosine-kinase inhibitor (TKI) responses poses a puzzling question to clinicians. Different variants of ALK rearrangements might be one of the mechanisms explaining this phenomenon. Therefore, identifying specific fusion forms is crucial… read more here.
Keywords: adenocarcinoma patient; alk; lung adenocarcinoma; one lung ... See more keywords